Did You Know...
...In 1790, the cost to obtain a patent was between $4 and $5.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 5871943 | Immunoassay comprising a truncated pneumococcal surface protein A (PspA) A purified pneumococcal surface protein A (PspA) comprises a truncated form of the PspA protein which is immunoprotective and contains the protective epitopes of PspA. The PspA protein is soluble in physiologic solution and lacks at least the cell membran... | 02/16/1999 |
| 5871740 | Methods of using poxvirus p35 as a chemokine inhibitor and compositions therefore A protein designated p35 binds to a number of the chemotaxis-stimulating cytokines known as chemokines. p35 may be used to treat conditions that are mediated by chemokines, such as inflammation. p35 is a secreted protein that can be purified from the cult... | 02/16/1999 |
| 5871738 | Nematode vaccine Disclosed is a substantially purified antigen derived from a first parasitic nematode species which, when administered to a host animal, is capable of protecting the host animal from infestation by a second parasitic nematode species, wherein the first an... | 02/16/1999 |
| 5869057 | Recombinant vaccines to break self-tolerance This invention relates to vaccines, specifically to the use of recombinant DNA technology to immunize against self proteins and to induce antibody against self protein in mammals. A process is described in which DNA sequences encoding a microbial gene pro... | 02/09/1999 |
| 5869058 | Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines The invention relates to conjugates of poorly immunogenic antigens, e.g., peptides, proteins and polysaccharides, with a synthetic peptide carrier constituting a T cell epitope derived from the sequence of E. coli hsp65 (GroEL), or an analog thereof, said... | 02/09/1999 |
| 5866132 | Immunogenic oligosaccharide compositions The invention provides immunogenic oligosaccharide compositions and methods of making and using them. In particular, the compositions comprise oligosaccharides covalently coupled to carrier protein, wherein the resultant conjugate has been shown to contai... | 02/02/1999 |
| 5866335 | Preparation of derivatized 10,10'-substituted-9,9'-biacridine luminescent molecules and signal solutions The synthesis of 10,10'-substituted-9,9'-biacridine molecules and their derivatives is disclosed. These molecules are shown to catalyze the production of light by chemiluminescence in the presence of a signal solution having at a pH from about 10.0 to abo... | 02/02/1999 |
| 5861262 | Method of the specific immunoassay of human plasma glutathione peroxidase, kit for its implementation, oligopeptides and antibodies specific for the method An oligopeptide having an amino acid sequence Glu Pro Gly Asn Ser Glu Ile Leu Pro Thr Leu Lys and variants thereof; immunogenic conjugates obtained therefrom; antibodies produced by means of said conjugates and which specifically recognize human plasma glutath... | 01/19/1999 |
| 5858729 | Expression of porcine reproductive respiratory syndrome virus polypeptides in the same cell The present invention provides a process for the recombinant DNA production of a mature form of the PRRSV ORF 3 or ORF 4 protein. This is achieved by the co-expression of the PRRSV ORF 2, ORF 3 and ORF 4 proteins by the same cell.... | 01/12/1999 |
| 5858362 | Conjugate vaccine for group B Streptococcus A vaccine capable of protecting a recipient from infection caused by group B Streptococcus. The vaccine provides polysaccharide-protein moieties and contain (a) a group B Streptococcus polysaccharide conjugated to (b) a functional derivative of a group B ... | 01/12/1999 |
| 5856437 | Hepatitis C virus isolate polypeptides Two new isolates of the Hepatitis C virus (HCV), J1 and J7, are disclosed. These new isolates comprise nucleotide and amino acid sequences which are distinct from the prototype HCV isolate, HCV1. Thus, J1 and J7 provide new polynucleotides and polypeptide... | 01/05/1999 |
| 5856451 | Method for reducing respiratory allergenicity The invention relates to modified polypeptides with reduced allergenicity comprising a parent polypeptide with a molecular weight from between 10 kDa and 100 kDa conjugated to a polymer with a molecular weight (Mr) in the range of 1 kDa and 60 ... | 01/05/1999 |
| 5856442 | Transcripts of the MHC class I HLA-G gene and their applications Transcripts of the major histocompatibility complex (MHC) Class I HLA-G gene which are present in foetal trophoblasts and/or in adult circulating mono-nuclear cells, as well as methods of using these. Either the said transcripts comprise, in succession in... | 01/05/1999 |
| 5854206 | Compounds and methods for treatment and diagnosis of prostate cancer Compounds and methods for treating and diagnosing prostate cancer are disclosed. The compounds provided include polypeptides that contain at least a portion of a secreted or cell associated prostate cell protein. Such polypeptides may be formulated into v... | 12/29/1998 |
| 5849599 | Method for making a preconjugate A method for making a preconjugate which includes immunogenic species of a polymorphic analyte. The method is carried out by reacting an activated binding moiety, and a polymorphic analyte at room temperature for between about 10 hours and about 60 hours.... | 12/15/1998 |
| 5849301 | Producing immunogenic constructs using soluable carbohydrates activated via organic cyanylating reagents The invention relates to a process for producing an immunogenic construct comprising activating at least one first carbohydrate-containing moiety with CDAP, CTEA or pNPC, and covalently joining the activated first moiety to a second moiety. Preferably, th... | 12/15/1998 |
| 5846826 | Isolated cytolytic T cell line specific to complexes of HLA-B44 molecules and specific nonapeptides The invention involves cytolytic T cell lines which are specific for complexes of HLA-B44 molecules and nonamers which bind to these.... | 12/08/1998 |
| 5846537 | Modified avidin and streptavidin and methods of use thereof The present invention provides modified avidin and streptavidin compounds that have suitable blood clearance kinetics for use in a two-step approach to deliver a molecule to a target site. In particular, to hasten SA's blood clearance carbohydrate moietie... | 12/08/1998 |
| 5843450 | Hepatitis GB Virus synthetic peptides and uses thereof Hepatitis GB Virus (HGBV) synthetic peptides useful for a variety of diagnostic and therapeutic applications, kits for using the HGBV nucleic acid or amino acid sequences and antibodies which specifically bind to HGBV. Also provided are methods for produc... | 12/01/1998 |
| 5843882 | Antiviral proteins and peptides The present invention provides antiviral proteins, peptides and conjugates, as well as methods of obtaining these agents. The antiviral proteins, peptides and conjugates of the present invention can be used alone or in combination with other antiviral age... | 12/01/1998 |
| 5843682 | N-1-carboxyalkyl derivatives of LSD Novel derivatives of LSD having the formula ##STR1## wherein R1 is an alkyl, cycloalkyl or aryl group having 1 to 10 carbon atoms, preferably an alkyl group having 1 carbon atom; R2 is a bond or ##STR2## wherein R3 | 12/01/1998 |
| 5843461 | Group B streptococcus type II polysaccharide-tetanus toxoid conjugate vaccines This invention relates to antigenic conjugate molecules comprising the capsular polysaccharide of Group B streptococcus type II which are covalently linked to protein. This invention also relates to vaccines and methods of immunizing mammals, including hu... | 12/01/1998 |
| 5843444 | Conjugate vaccine for group B streptococcus A vaccine capable of protecting a recipient from infection caused by group B Streptococcus. The vaccine provides polysaccharide-protein moieties and contain (a) a group B Streptococcus polysaccharide conjugated to (b) a functional derivative of a group B ... | 12/01/1998 |
| 5840834 | Technique for joining amino acid sequences and novel composition useful in immunoassays Two amino acid sequences are joined together using an electron acceptor moiety and a linking moiety, such as a chelating agent. In particular, an amino acid sequence specific for binding to a material interest is linked to an enzyme which acts on an indic... | 11/24/1998 |
| 5840305 | Treatment of HIV-Infection by interfering with host cell cyclophilin receptor activity The present invention relates to therapeutic modalities and pharmaceutical compositions for the treatment of HIV-infection using cyclophilin A and its corresponding human cellular binding partner or receptor as a target for intervention. The present inven... | 11/24/1998 |
| 5837477 | T cell receptor ligands and methods of using same The present invention concerns TCR ligands with immunomodulatory properties, as well as methods of identifying such ligands and of using such ligands to modulate T cell effector responses.... | 11/17/1998 |
| 5837825 | Campylobacter jejuni flagellin/Escherichia coli LT-B fusion protein A fusion protein which comprises the B subunit of the labile toxin (LT-B) of E. coli and part of the flagellin (flaA) protein of C. jejuni is antigenic and is useful for decreasing colonization in chickens by Campylobacter species. The protein is produced... | 11/17/1998 |
| 5837251 | Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a compos... | 11/17/1998 |
| 5834594 | Polyethylene-protein conjugates The present invention is a physiologically active, substantially non-immunogenic water soluble polyethylene glycol protein conjugate having the same utility as the protein which forms the conjugate, without having the same properties of producing an immun... | 11/10/1998 |
| 5834210 | Stable troponin subunits and complexes Stable troponin subunits and complexes and methods for their preparation are described. Among other uses, these subunits and complexes are useful as antigens for the preparation of antibodies, and as controls and calibrators for troponin assays. One compl... | 11/10/1998 |
| 5830634 | Peptides derived from a retrovirus of the HIV group and their use Immunologically active peptides which are derived from a novel immunodeficiency virus which has the designation MVP5180/91 are described. A diagnostic composition containing such a peptide and methods of detecting an antibody against a retrovirus that cau... | 11/03/1998 |
| 5827673 | Method of detecting myocardial infarction The present invention provides a method of detecting and diagnosing myocardial infarction which detects myocardial infarction by immunoassay using a monoclonal antibody having specific reactivity for human hepatocyte growth factor (HGF) as obtained by usi... | 10/27/1998 |
| 5824310 | Lipopplysaccharide conjugate vaccines The present invention relates to lipopolysaccharides from Brucella abortus and their use as carriers in vaccines for humans and animals. In particular, the present invention relates to conjugate molecules having a carrier molecule of purified lipopolysacc... | 10/20/1998 |
| 5824777 | Attenuated measles virus vaccine containing specific nucleotide sequence and a method for its absolute identification A measles vaccine virus AIK-C strain comprises genomic RNA that produces by reverse transcription cDNA having a specific nucleotide sequence indicative of the viral genomic RNA in the seed virus for measles vaccine or measles virus vaccine. The complete s... | 10/20/1998 |
| 5821342 | Carbamazepine derivatives/antigens The present invention provides a novel carbamazepine hydrazide compound suitable for covalent attachment to a polymer particle reagent, having the general formula ##STR1## The present invention also provides a novel carbamazepine acid compound s... | 10/13/1998 |
| 5820860 | Conjugate vaccine for group B streptococcus A vaccine capable of protecting a recipient from infection caused by group B Streptococcus. The vaccine provides polysaccharide-protein moieties and contain (a) a group B Streptococcus polysaccharide conjugated to (b)) a functional derivative of a group B... | 10/13/1998 |
| 5820866 | Product and process for T cell regulation The present invention relates to a product and process for regulating the activity of T cells using major histocompatibility complexes (MHC) stably linked to antigenic peptides. Disclosed is an antigenic peptide covalently linked to a major histocompatibi... | 10/13/1998 |
| 5817315 | Recombinant vaccine A method for an induction of immune response against polypeptide employing antigenic presentation of said polypeptide in the form of either fusion protein with MHC product amino acid sequence or tertiary complex with MHC product on natural or artificial m... | 10/06/1998 |
| 5817753 | Antigenic modification of polypeptides Endogenous and exogenous proteins, and fragments thereof, are chemically modified outside the body of an animal so that when injected into the animal they produce more antibodies against the unmodified protein than would injection of the unmodified protei... | 10/06/1998 |
| 5814459 | Phosphospecific transcription factor antibodies Phospho-specific antibodies which recognize the phosphorylated forms of cAMP-responsive transcription factors are provided.... | 09/29/1998 |
